The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is up 27% year to date and 30% over the past year, ahead of the Nasdaq 100, which returned 19% year to date and 26% over the past year. For a fund built to sit in retirement accounts and pay a rising qualified dividend, that is the kind of year that draws attention it usually does not want.
The reversal in SCHD is really two stories. The first is macro: value has beaten growth as investors pulled back on the multiple they will pay for megacap AI spenders, and a fund structurally underweight technology finally benefits from what used to hurt it. The second is mechanical: SCHD went through one of its largest index reconstitutions in late March, and the portfolio producing this year’s number is materially different from the one holders owned in January.
What the Rotation Actually Rewarded
SCHD’s mandate screens for durable dividend payers, which naturally tilts the fund toward healthcare, consumer staples, energy, and financials, and away from unprofitable or reinvestment-heavy technology. For years, that tilt was a drag while the market paid up for growth.
This year the trade reversed. As skepticism about AI capital spending compressed valuations on the largest growth names, capital moved toward companies with visible free cash flow and conservative payout policies, which is essentially SCHD’s shopping list.
The fund’s current sector weights show why it benefited. Healthcare sits at roughly 18% of assets, energy at about 14%, consumer staples at near 13%, and technology at around 13%. Compared to a market-cap index, that mix was engineered for exactly this environment.
The March Reconstitution Changed the Portfolio
The fund a holder owns today differs materially from the one held in January. The March rebalance brought heavy turnover, trimming energy weight and adding higher-quality names, including semiconductor payers now sitting near the top of the book.
The current top holdings reflect that. Qualcomm (NASDAQ:QCOM | QCOM Price Prediction) and Texas Instruments (NASDAQ:TXN) are now the two largest positions, ahead of UnitedHealth (NYSE:UNH). Those additions helped this year because chip payers rallied alongside the broader semiconductor complex, without SCHD having to own the expensive parts of that trade.
The fund has grown to roughly $95 billion in net assets as of May, and inflows have followed the performance. Dividend ETFs typically gather money after strong years rather than before them.
Which Cause Is Doing More Work
The macro rotation is doing more of the work than the reconstitution does, although the two reinforce each other. Value was already beating growth before March, and SCHD’s older portfolio would have participated in that trade even without a rebalance.
The reconstitution added incremental return by shifting into names that benefited from the semiconductor recovery, but the direction of travel was set by what investors were willing to pay for growth, not by what Schwab’s index committee did in March.
That distinction matters for anyone buying today. If the return came mostly from rotation, then chasing SCHD after a 27% year is chasing a factor trade that has already run. If it came mostly from the new portfolio, then the fund a buyer gets today is roughly the fund that produced the return. The likely answer is a mix, weighted toward rotation, which argues for owning SCHD for what it does over a decade rather than for what it did over eight months.
Where SCHD Fits Now
SCHD still does the job it was designed for. The trailing twelve-month distribution is $1.05 per share, paid quarterly, and the qualified nature of those dividends makes the fund more efficient in taxable accounts than most covered-call income products.
For an investor at or near retirement, the case is a rising qualified dividend stream from companies with real earnings, held at a low expense ratio, with sector composition that will drift as the index rescreens each year. What changed is the entry price. Shares are around $34, and buying after a 27% run means accepting a lower forward yield than holders who bought in prior years received.
SCHD fits as a core dividend holding for investors who want qualified income and can accept that a year like this one is not the base case. Anyone buying it as a growth substitute because it beat the Nasdaq 100 this year is buying the wrong fund for the wrong reason.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks